Health and Healthcare
Aurinia Pharma's Dry Eye Study Blanks on Late-Stage Results
Published:
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares slid on Tuesday after the company reported results from its midstage study for the treatment of dry eye syndrome (DES). Unfortunately, the topline results did not live up to expectations, and the firm has decided to suspend development of the program.
In terms of the specifics, the firm announced topline data from the Phase 2/3 Audrey clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of DES.
The trial did not achieve statistical significance on its primary endpoint of a 10mm or greater improvement in Schirmer Tear Test at four weeks between active dose groups of VOS compared to vehicle.
Based on these initial topline results that Aurinia is continuing to interrogate, management is suspending the DES program at this time.
Separately, the initial analysis of these secondary outcomes suggests dose-dependent activity and safety were observed across dose groups compared to vehicle. However, further analysis must be done over the coming weeks.
Ultimately, the firm was surprised by these results, but management has decided to remain focused on preparing voclosporin for a different indication, lupus nephritis. This other indication has a different formulation and delivery mechanism compared to VOS.
Excluding Tuesday’s move, Aurinia Pharmaceuticals stock had underperformed the broad markets with a retreat of 23% year to date. In the past 52 weeks, the share price was actually up 202%.
Aurinia Pharmaceuticals stock traded down about 13% at $13.44 on Tuesday, in a 52-week range of $4.90 to $21.93. The consensus price target is $11.92.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
